Search Results

You are looking at 171 - 180 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M. Boughan, Bouthaina Dabaja, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Alex F. Herrera, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Matthew McKinney, Monika Metzger, David Morgan, Carolyn Mulroney, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

ABVD ( P <.001). The 5-year PFS rate was 95.4% and 89.1%, respectively ( P <.001). 73 The 5-year OS rate was not significantly different between the 2 arms (97.2% and 96.8%, respectively; P =.731). The rate of progression or relapse was also lower in

Full access

Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia

Hany Elmariah and Keith W. Pratz

prevent relapse. 1 In patients at high risk of relapse due to advanced age, unfavorable cytogenetics or molecular mutations, AML secondary to an antecedent hematologic malignancy, or relapsed/refractory disease, an allogeneic hematopoietic cell transplant

Full access

Supportive Therapies in Multiple Myeloma

Charise Gleason, Ajay Nooka, and Sagar Lonial

Sonneveld P Schuster MW . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma . N Engl J Med 2005 ; 352 : 2487 – 2498 . 6 Richardson PG Sonneveld P Schuster MW . Reversibility of symptomatic peripheral neuropathy with

Full access

Allogeneic Hematopoietic Cell Transplantation for AML—A Missed Opportunity!

Margaret R. O'Donnell

remission with intermediate- and high-risk disease based on cytogenetic and molecular characteristics and patients with induction failure or relapsed disease should be referred for transplant evaluation, with a generous fudge factor to weed out “unfit” older

Full access

Diffuse Large B-Cell Lymphoma Version 1.2016

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

marrow) are associated with increased risk for developing central nervous system (CNS) relapse. 21 – 23 The German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) recently proposed a prognostic model to predict the risk of CNS relapse incorporating

Full access

Who Benefits From Maintenance Therapy in Acute Promyelocytic Leukemia?

Edmond Marzbani and Elihu Estey

-containing chemotherapy and achieves molecular remission rates of 95%. Standard practice is including ATRA in consolidation, because historical comparisons suggest reduced relapse risk when used in conjunction with chemotherapy. Evidence has emerged that in high

Full access

CLO20-041: Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy

Jung Julie Kang, Hannah Verma, Kaveh Zakeri, Huili Wang, Dan Fan, Ming Fan, Anna Lee, Sarin Kitpanit, Linda Chen, Yao Yu, C. Jillian Tsai, Sean McBride, Nadeem Riaz, Daphna Gelblum, Alan S. Ho, Eric Sherman, Lara Dunn, Jay O. Boyle, Richard J. Wong, Ian Ganly, and Nancy Y. Lee

RT at Memorial Sloan Kettering Cancer Center from 2010 to 2018 were retrospectively reviewed. The Kaplan-Meier method was used to estimate local relapse free survival (LRFS), regional relapse free survival (RRFS), distant metastasis free survival

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin's Lymphoma Subtypes: A Phase I Study Principal

Full access

Updates to the Management of Chronic Lymphocytic Leukemia

William G. Wierda

, including elderly patients and those with relapsed or refractory del(17p), in terms of overall response rate, duration of response, and PFS. In the phase III trial, 9 where ibrutinib was compared with ofatumumab in relapsed or refractory disease, overall

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer, and Hema Sundar

-stimulated karyotype of CLL cells) may be a stronger predictor of poor clinical outcomes than del(17p) or TP53 mutation in patients with CLL treated with ibrutinib-based regimens. 59 – 64 In a multivariate analysis, among patients with relapsed/refractory CLL